Treatment success reached 56.7% and total lesions fell 71.8% with up to 52 weeks of oral denifanstat, with no adverse event-related discontinuations.
|Articles|March 14, 2013
Dermatologists at risk! Fraud charges up during Obama administration [INFOGRAPHIC]
The total amount of fraud recoveries returned to Medicare trust funds since the start of the Obama administration is $10.7 billion. [Infographic]
Advertisement
The total amount of fraud recoveries returned to Medicare trust funds since the start of the Obama administration is $10.7 billion. Check out the graphic below describing the rising number of fraud charges since 2006. And read more
National report - At first, dermatologists seemed unlikely to be the subject of audits, but that is no longer the case. And it’s not only Medicare and Medicaid trying to recoup funds and find fraud - commercial carriers are as well. It’s a perfect storm for increasing medical audits at all types of physician practices - including dermatology. One of President Obama's long-standing priorities has been fighting Medicare fraud, and the fiscally malnourished U.S. government needs to find money. Uncovering healthcare fraud is a proven moneymaker.
Read more >>
Advertisement
Related to this article
Late-breaking EADV 2026 data showed significant improvements in skin clearance, itch, pain, and patient satisfaction among patients treated with lebrikizumab.
Day 1 of EADV 2026 brought new data across atopic dermatitis, cutaneous lupus, skin cancer, AI, climate-related skin disease, and more.
Up to 91% of patients reached EASI-75 and up to 67% reached IGA 0/1 at week 152, with no new safety signals, according to Galderma's EADV 2026 data.
Two studies presented at EADV 2026 highlight misinformation and dermatologic complications linked to viral skincare routines on social media.
Phase 2 data presented at EADV 2026 showed daxdilimab significantly reduced disease activity and improved response rates in treatment-refractory DLE.
Presented as a late breaker at EADV 2026, mid-dose zumilokibart achieved EASI-75 in 65.9% of adults with atopic dermatitis vs 23.4% with placebo at week 16.
This review of the latest dermatological studies includes insights on ruxolitinib for lichen planus, early vitiligo treatment, psoriasis response, AD disease control, and PFB management.
Advertisement
Advertisement
Trending on Dermatology Times
1
Late Breaking: Zumilokibart Meets Primary End Point in Phase 2 Atopic Dermatitis Trial
2
Daxdilimab Improves Disease Activity in Treatment-Refractory Discoid Lupus in Phase 2 Trial
3
Dupilumab Data at EADV 2026 Highlight Outcomes Across AD, CSU, and Prurigo Nodularis
4
Nearly 95% of Viral Korean Skincare TikTok Videos Contain Misleading Claims
5